Open Outbreak

我应该担心抗微生物耐药性吗?

更新于 · 依据官方评估分级;此处内容不构成医疗建议。

抗微生物耐药性 · 关注度: 较高

如果您在受影响地区 无评估
没有机构发布针对受影响地区人群的抗微生物耐药性整体评估;UKHSA和PAHO已发布针对英格兰和美洲的监测更新。
如果您在同一国家或地区的其他地方 无评估
没有机构发布针对同一国家或地区其他地方人群的抗微生物耐药性整体评估;UKHSA和PAHO的更新描述了耐药趋势,而不是您面临的风险水平。
如果您即将前往那里 无评估
没有机构发布针对旅行者的抗微生物耐药性整体评估;WHO的通知涉及耐药的超致病性克雷伯氏肺炎菌,而不是特定于旅行的评估。
如果您在世界其他地方 中
WHO assessed the global risk from resistant hypervirulent Klebsiella pneumoniae as moderate on 31 July 2024. This applies to that organism, not to antimicrobial resistance as a whole or to a new November 2026 outbreak. 根据 WHO

正在发生什么

Antimicrobial resistance is a long-running worldwide problem involving drug-resistant bacteria and fungi, not a single outbreak with one starting date or a worldwide case total. In its official update on 12 November 2026, UKHSA reported 21,129 antibiotic-resistant bloodstream infections in England in 2025, with growth slowing to 3.2%, and 2,318 deaths among people with resistant Gram-negative bloodstream infections—not necessarily deaths attributable to resistance. In its official update on 18 November 2026, PAHO reported that carbapenem resistance in Klebsiella pneumoniae rose from approximately 15% in 2015 to 26% in 2024 across 15 reporting countries in Latin America and the Caribbean; these are historical surveillance findings, not new November outbreak counts. Media coverage includes an unverified projection of 39 million deaths over 25 years, which must not be read as deaths newly recorded this month. Officials are strengthening surveillance and laboratories, promoting infection prevention and responsible prescribing, and improving access to effective antibiotics; the latest updates do not establish a sudden worldwide surge.

谁会受影响以及如何传播

抗微生物耐药性意味着细菌或真菌不再可靠地被以前有效的药物阻止,使感染更难治疗。它影响许多不同感染的人,包括医疗环境中的血流感染和社区获得的感染。耐药性可以通过基因变化产生,然后随着耐药病原体在人员之间、医疗环境和更广泛的环境中传播而扩散;传播途径取决于生物体。白色念珠菌与医疗传播相关,而WHO报告称,耐药的超致病性克雷伯氏肺炎菌已在所有六个WHO地区被报告,并可能在实验室能力有限的地方被遗漏。

我们关注的事项

更新

来源